Neoadjuvant chemotherapy in oesophageal adenocarcinoma

[...]the toxicity of the CROSS regimen is mild with an incidence of clinically relevant grade 3-4 toxicities of 5% or less. MCCMH declares no competing interests. 1 D Alderson, D Cunningham, M Nankivell, Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed b...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 18; no. 11; p. e639
Main Authors van Laarhoven, Hanneke W M, van Berge Henegouwen, Mark I, Hulshof, Maarten C C M
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2017
Elsevier Limited
Subjects
5-Fluorouracil
Adenocarcinoma
Cancer
Chemoradiotherapy
Chemotherapy
Chemotherapy, Adjuvant
Esophageal Neoplasms
Esophagus
Humans
Neoadjuvant Therapy
Research funding
Surgery
Toxicity
Online AccessGet full text

Cover

More Information
Summary:[...]the toxicity of the CROSS regimen is mild with an incidence of clinically relevant grade 3-4 toxicities of 5% or less. MCCMH declares no competing interests. 1 D Alderson, D Cunningham, M Nankivell, Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial, Lancet Oncol, Vol. 18, 2017, 1249-1260 2 E Ter Veer, N Haj Mohammad, G van Valkenhoef, The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysis, J Natl Cancer Inst, Vol. 108, 2016, djw166 3 J Shapiro, JJ van Lanschot, MC Hulshof, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, Lancet Oncol, Vol. 16, 2015, 1090-1098 4 P van Hagen, MC Hulshof, JJ van Lanschot, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, Vol. 366, 2012, 2074-2084
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(17)30812-4